<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01788605</url>
  </required_header>
  <id_info>
    <org_study_id>CBMTC-supp001</org_study_id>
    <nct_id>NCT01788605</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Ramosetron in the Setting of Hematopoietic Stem Cell Transplantation</brief_title>
  <official_title>Prospective, Single-arm Phase 2 Trial to Evaluate Efficacy and Safety of Ramosetron in the Setting of Hematopoietic Stem Cell Transplantation for Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Catholic University of Korea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Catholic University of Korea</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. The purpose of this study is to determine the efficacy of ramosetron for the prevention&#xD;
           of emesis and the control of nausea and vomiting despite of the prophylactic antiemetic&#xD;
           treatment during hematopoietic stem cell transplantation&#xD;
&#xD;
        2. The study hypothesis is that ramosetron is effective for the prevention of emesis and&#xD;
           control of emesis and/or vomiting that develop after the prophylactic antiemetic therapy&#xD;
           in the setting of hematopoietic stem cell transplantation&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2014</start_date>
  <completion_date type="Anticipated">February 2015</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>efficacy of ramosetron in terms of complete response (no emesis, no rescue therapy) during the conditioning regimen and within 3 or 6 days after the end of the conditioning regimen</measure>
    <time_frame>within 1 week after the end of conditioning regimen</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>the efficacy of second dose of ramosetron for the treatment of breakthrough emesis</measure>
    <time_frame>within 1 week after the end of conditioning regimen</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>the number of vomiting episodes</measure>
    <time_frame>within 1 week after the end of conditioning regimen</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>grade of nausea and need for rescue therapy</measure>
    <time_frame>within 1 week after the end of conditioning regimen</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">65</enrollment>
  <condition>Hematologic Malignancies</condition>
  <arm_group>
    <arm_group_label>ramosetron</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ramosetron</intervention_name>
    <arm_group_label>ramosetron</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients undergoing hematopoietic stem cell transplantation conditioned with highly or&#xD;
             moderately emetogenic drugs or total body irradiation (TBI) for hematologic&#xD;
             malignancies&#xD;
&#xD;
          2. aged over 18 yrs&#xD;
&#xD;
          3. Eastern Cooperative Oncology Group (ECOG) performance status 0 - 2&#xD;
&#xD;
          4. patients who are able to take oral medications&#xD;
&#xD;
          5. patients who get well-informed and sign the consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients complicating&#xD;
&#xD;
               -  severe hypertension (systolic blood pressure &gt; 210 mmHg or diastolic blood&#xD;
                  pressure &gt; 120 mmHg)&#xD;
&#xD;
               -  significant heart disease such as congestive heart failure&#xD;
&#xD;
               -  renal insufficiency (serum Cr &gt;= 3.0 mg/dL)&#xD;
&#xD;
               -  liver disease (Aspartate aminotransferase (AST), alanine aminotransferase (ALT) &gt;&#xD;
                  3 upper normal limit; alkaline phosphatase (ALP) &gt; 2 upper normal limit)&#xD;
&#xD;
          2. Patients complicated by conditions such as gastrointestinal obstruction or active&#xD;
             peptic ulcer causing emesis&#xD;
&#xD;
          3. Patients with brain tumor, brain metastasis and epilepsy&#xD;
&#xD;
          4. Patients with the history of extrapyramidal symptom&#xD;
&#xD;
          5. Patients with the history of allergy to serotonin antagonists&#xD;
&#xD;
          6. pregnant or lactating women&#xD;
&#xD;
          7. Patients with drug abuse or psychiatric illness, or patients who are not capable of&#xD;
             the normal communications&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Catholic Blood &amp; Marrow Transplantation Center, Seoul St Mary's Hospital, the Catholic University of Korea</name>
      <address>
        <city>Seoul</city>
        <zip>137-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bo-Kyung Kim, RN</last_name>
      <phone>82-50-7448-6371</phone>
      <email>mikaella7@naver.com</email>
    </contact>
    <contact_backup>
      <last_name>Ki-Seong Eom, MD</last_name>
      <phone>82-2-2258-6056</phone>
      <email>dreom@catholic.ac.kr</email>
    </contact_backup>
    <investigator>
      <last_name>Jong-Wook Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <study_first_submitted>February 7, 2013</study_first_submitted>
  <study_first_submitted_qc>February 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2013</study_first_posted>
  <last_update_submitted>December 5, 2014</last_update_submitted>
  <last_update_submitted_qc>December 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Catholic University of Korea</investigator_affiliation>
    <investigator_full_name>Ki-Seong Eom, MD</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>hematologic malignancies</keyword>
  <keyword>hematopoietic stem cell transplantation</keyword>
  <keyword>ramosetron</keyword>
  <keyword>emesis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ramosetron</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

